Articles

< Previous         Next >  
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1 Free
Qing Xu1, Yue Jiang2,3, Yu Yin1,4, Qi Li1, Jun He2, Yi Jing2, Yan-Ting Qi2, Qian Xu1, Wei Li1, Bo Lu5, Stephen S. Peiper2, Bing-Hua Jiang1,2,*, and Ling-Zhi Liu2,*
1State Key Lab of Reproductive Medicine, and Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing 210029, China
2Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
3Faculty of Software, Fujian Normal University, Fuzhou 350007, China
4Department of Pathology, Anhui Medical University, Hefei 230032, China 5Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA *Correspondence to:Bing-Hua Jiang, E-mail: binghjiang@yahoo.com; Ling-Zhi Liu, E-mail: ling-zhi.liu@jefferson.edu
J Mol Cell Biol, Volume 5, Issue 1, February 2013, 3-13,  https://doi.org/10.1093/jmcb/mjs049
Keyword: miR-148a, miR-152, DNMT1, IGF-IR, IRS1, breast cancer, tumor angiogenesis

Dysregulation of microRNAs is a common feature in human cancers, including breast cancer (BC). Here we describe the epigenetic regulation of miR-148a and miR-152 and their impact on BC cells. Due to the hypermethylation of CpG island, the expression levels of both miR-148a and miR-152 (miR-148a/152) are decreased in BC tissues and cells. DNMT1, the DNA methyltransferase 1 for the maintenance methylation, is aberrantly up-regulated in BC and its overexpression is responsible for hypermethylation of miR-148a and miR-152 promoters. Intriguingly, we found that DNMT1 expression, which is one of the targets of miR-148a/152, is inversely correlated with the expression levels of miR-148a/152 in BC tissues. Those results lead us to propose a negative feedback regulatory loop between miR-148a/152 and DNMT1 in BC. More importantly, we demonstrate that IGF-IR and IRS1, often overexpressed in BC, are two novel targets of miR-148a/152. Overexpression of miR-148a or miR-152 significantly inhibits BC cell proliferation, colony formation, and tumor angiogenesis via targeting IGF-IR and IRS1 and suppressing their downstream AKT and MAPK/ERK signaling pathways. Our results suggest a novel miR-148a/152-DNMT1 regulatory circuit and reveal that miR-148a and miR-152 act as tumor suppressors by targeting IGF-IR and IRS1, and that restoration of miR-148a/152 expression may provide a strategy for therapeutic application to treat BC patients.